Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid crawled date : 2021 - 07 - 12 save search
In Response to Rare Guillain-Barré Cases, FDA Plans New Warning for J&J COVID...
Published: 2021-07-12 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.32%
H: 0.85%
C: -0.15%
covid fda response rare
In Response to Rare Guillain-Barré Cases, FDA Plans New Warning for J&J COVID-19 Vaccine
Published: 2021-07-12 (Crawled : 21:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.32%
H: 0.85%
C: -0.15%
covid fda vaccine response covid-19 rare
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
Published: 2021-07-12 (Crawled : 20:00) - prnewswire.com
ARDS | $0.066 2.82% 28K
|
Health Technology
|
| O: -2.19%
H: 1.26%
C: -14.99%
covid sars-cov-2
QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook for declining COVID-19 test trends and plans new $100 million share repurchase program
Published: 2021-07-12 (Crawled : 19:00) - biospace.com/
QGEN | $39.47 0.61% 0.0% 950K
|
Health Technology
|
| O: 1.37%
H: 0.33%
C: -4.73%
QGEN | $39.47 0.61% 0.0% 950K
|
Health Technology
|
| O: 1.37%
H: 0.33%
C: -4.73%
covid test results
Evidence Building for a Mix and Match Approach to COVID-19 Vaccines
Published: 2021-07-12 (Crawled : 16:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.32%
H: 0.85%
C: -0.15%
covid vaccine covid-19
NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine
Published: 2021-07-12 (Crawled : 15:15) - prnewswire.com
NRXP | News 0 d | $3.025 -27.63% -38.18% 760K
|
Manufacturing
|
| O: -2.09%
H: 31.85%
C: -14.37%
URGN | $14.32 0.56% 0.56% 320K
|
Health Technology
|
| O: -0.74%
H: 0.74%
C: 0.2%
PYPD | $4.3 -3.15% -3.26% 5.2K
|
Health Technology
|
| O: 4.35%
H: 0.0%
C: -4.5%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.93%
H: 1.22%
C: -0.23%
GLMD | $0.3669 -0.41% -0.41% 27K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -2.74%
covid israel partnership commercialization vaccine research
Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine
Published: 2021-07-12 (Crawled : 14:15) - biospace.com/
MRNA | News S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.79%
H: 4.94%
C: 3.62%
covid vaccine covid-19
Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19
Published: 2021-07-12 (Crawled : 14:00) - biospace.com/
ADTX | $2.37 0.85% 0.84% 55K
|
Health Technology
|
| O: 0.8%
H: 5.16%
C: 3.97%
covid test antibody response covid-19
NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ (Aviptadil) in the I-SPY COVID Trial
Published: 2021-07-12 (Crawled : 13:00) - prnewswire.com
NRXP | News 0 d | $3.025 -27.63% -38.18% 760K
|
Manufacturing
|
| O: -2.09%
H: 31.85%
C: -14.37%
covid treatment trial aviptadil
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Published: 2021-07-12 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -1.15%
H: 1.13%
C: 0.0%
covid disease phase 2 europe infectious disease phase 2/3 antiviral results molnupiravir
New Lightspeed study sheds light on impact of COVID-19 on LGBTQ+ businesses in North America
Published: 2021-07-12 (Crawled : 11:00) - prnewswire.com
LSPD | $12.99 -0.84% 0.0% 640K
|
Technology Services
|
| O: 4.14%
H: 0.19%
C: -1.72%
covid covid-19
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
Published: 2021-07-12 (Crawled : 07:00) - globenewswire.com
BPTS | $0.329 13.29% 11.73% 340K
|
Manufacturing
| Email alert
Add to watchlist
positive covid preclinical covid-19 pre-clinical
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.